341 related articles for article (PubMed ID: 15073267)
21. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
22. Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain.
Lahoutte T; Mertens J; Caveliers V; Franken PR; Everaert H; Bossuyt A
J Nucl Med; 2003 Sep; 44(9):1489-94. PubMed ID: 12960197
[TBL] [Abstract][Full Text] [Related]
23. Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring.
Kawai H; Toyohara J; Kado H; Nakagawa T; Takamatsu S; Furukawa T; Yonekura Y; Kubota T; Fujibayashi Y
Nucl Med Biol; 2006 Jan; 33(1):29-35. PubMed ID: 16459256
[TBL] [Abstract][Full Text] [Related]
24. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
Lu L; Jiang L; Guan H; Gao Y; Lu H
Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
[TBL] [Abstract][Full Text] [Related]
25. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
[TBL] [Abstract][Full Text] [Related]
26. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
[TBL] [Abstract][Full Text] [Related]
27. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
[TBL] [Abstract][Full Text] [Related]
28. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice.
Lee KH; Ko BH; Paik JY; Jung KH; Choe YS; Choi Y; Kim BT
J Nucl Med; 2005 Sep; 46(9):1531-6. PubMed ID: 16157537
[TBL] [Abstract][Full Text] [Related]
29. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
[TBL] [Abstract][Full Text] [Related]
30. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
[TBL] [Abstract][Full Text] [Related]
32. Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions.
Sugae S; Suzuki A; Takahashi N; Minamimoto R; Cheng C; Theeraladanon C; Endo I; Togo S; Inoue T; Shimada H
Ann Nucl Med; 2008 Jan; 22(1):65-72. PubMed ID: 18250989
[TBL] [Abstract][Full Text] [Related]
33. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
[TBL] [Abstract][Full Text] [Related]
34. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies.
Jacene HA; Ishimori T; Engles JM; Leboulleux S; Stearns V; Wahl RL
J Nucl Med; 2006 Jun; 47(6):950-6. PubMed ID: 16741304
[TBL] [Abstract][Full Text] [Related]
35. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions.
Zhao S; Kuge Y; Tsukamoto E; Mochizuki T; Kato T; Hikosaka K; Hosokawa M; Kohanawa M; Tamaki N
Eur J Nucl Med; 2001 Jun; 28(6):730-5. PubMed ID: 11440033
[TBL] [Abstract][Full Text] [Related]
36. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells.
van Waarde A; Been LB; Ishiwata K; Dierckx RA; Elsinga PH
J Nucl Med; 2006 Sep; 47(9):1538-45. PubMed ID: 16954564
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
[TBL] [Abstract][Full Text] [Related]
38. Impact of animal handling on the results of 18F-FDG PET studies in mice.
Fueger BJ; Czernin J; Hildebrandt I; Tran C; Halpern BS; Stout D; Phelps ME; Weber WA
J Nucl Med; 2006 Jun; 47(6):999-1006. PubMed ID: 16741310
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
[TBL] [Abstract][Full Text] [Related]
40. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies.
Vesselle H; Grierson J; Peterson LM; Muzi M; Mankoff DA; Krohn KA
J Nucl Med; 2003 Sep; 44(9):1482-8. PubMed ID: 12960196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
